Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
This study has been completed.
Study NCT00003091 Information provided by Hoag Memorial Hospital Presbyterian
First Received on November 1, 1999. Last Updated on May 10, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Cancer
Melanoma (Skin)
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Kidney Neoplasms
Melanoma
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
aldesleukin
recombinant interferon alfa
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon-alpha
Interferons
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group
Back to top of Main Content
